The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients ≥ 50 years from the Czech acute leukaemia clinical register (alert).
Neoplasma
; 60(5): 576-83, 2013.
Article
en En
| MEDLINE
| ID: mdl-23790178
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Donantes de Tejidos
/
Leucemia Mieloide Aguda
/
Trasplante de Células Madre Hematopoyéticas
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neoplasma
Año:
2013
Tipo del documento:
Article
País de afiliación:
República Checa